12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Other News

Genetic Technologies, Myriad Genetics diagnostic news

The U.S. Supreme Court is set to weigh in on the eligibility of gene patents. The court is hearing oral arguments on April 15 in Association for Molecular Pathology, et al. v. U.S. PTO, et al., a case over Myriad's U.S. patents covering the BRCA1 and BRCA2 genes. The court will review a 2-1 August ruling by the U.S. Court of Appeals for the Federal...

Read the full 304 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >